By rigorously selecting or genetically engineering tumor types composed of SHP2 growth‐independent tumor cells, we find that specific SHP2 inactivation promotes endothelial cell death and the involution of tumor vessels resulting in reduced tumor growth, without impacting the resting vasculature of normal tissues. This evidence concerns the gene PTPN11 and neoplasm.